Please rotate your screen
apply for a license

news & insights

SocialMedia-MIMETAS (1).jpg May 20, 2022

MIMETAS Expands HUB Organoid Technology License

Leiden, The Netherlands, May 3, 2022 – MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today…

read more
SocialMedia-OncologyClinicalCandidate.jpg April 29, 2022

Oncology clinical candidate developed

San Diego, California, April 28, 2022 – …

read more
LinkedIn posts.png November 10, 2021

Exclusive interview with Dr Carla Verissimo

Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive…

read more
PERSIST-SEQ.png September 2, 2021

New PERSIST-SEQ program launched

2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international…

read more
HBV infected liver organoid.jpg August 31, 2021

Link revealed between HBV infection and liver cancer

HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer.

read more
partnership.png August 18, 2021

New service partnership

VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that…

read more
Cystic fibrosis organoid swelling.png August 12, 2021

CF models for drug development

HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF)

read more
Jove paper.png August 5, 2021

Test epithelial barrier function

Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability.

read more
Copy of HUB News (6).png July 14, 2021

HUB at Innovation Parade

HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the …

read more
News and Insights infographics.png April 26, 2021

HUB and Yamaha for IVD

April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd.…

read more
Next-gen diagnostic center.png September 4, 2020

Next-gen diagnostics

Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced…

read more
Ovarian cancer organoids May 27, 2020

Ovarian cancer organoids

Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade…

read more
intestine hormones.png May 13, 2020

Understanding gut’s hormones

Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of…

read more
SARS-COV-2 COVID 19 May 1, 2020

SARS-CoV-2 infects gut cells

Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in…

read more
Message CEO Covid.png April 1, 2020

A message from our CEO

Dear Valued Customer,

On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to…

read more
genetic disease organoids.png February 20, 2020

Organoids for genetic disorders

Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology…

read more
Tumor organoids Financial Times.png December 10, 2019

HUB on Financial Times

On December 10, 2019 the Financial Times featured HUB Organoids™ in …

read more
tumor-organoids-drug-discovery.png October 17, 2019

PDX organoids in drug development

San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform…

read more
Organoids on a chip.png October 1, 2019


Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into…

read more
toxicology-organoids.png July 16, 2019

Epistem license HUB Technology

Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company…

read more
PDOs available at CrownBio.png May 19, 2019

HUB PDOs now at CrownBio

San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid…

read more
research group.png April 9, 2019

New partner: CrownBio

March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR…

read more
Yamaha Cell handler organoids.png February 1, 2019

New partner: Yamaha Motor

February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their…

read more

meet us

watch on demand (18).png October 11, 2021

EUROTOX 2021 | Poster 391

Discover how to reduce costly animal experiments and obtain a quick indication of your drug safety with Merel Derksen

read more
watch on demand (17).png October 6, 2021

EUROTOX 2021 | Poster 553

Dr. Pourfarzad presents data on the use of HUB Organoids as advanced modes to investigate ADME and safety

read more
watch on demand (9).png September 24, 2021

2021 EUROTOX virtual congress

HUB presents two posters at the 2021 EUROTOX virtuals congress. Meet the scientists behind the data.

read more
3D Tissue Models.png September 10, 2021

6th PREDiCT 3D Tissue Models

Meet our speaker Dr. Sylvia Boj discussing the next-gen models for…

read more
watch on demand (7).png September 1, 2021

2021 Organoids are us

New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening,…

read more
watch on demand (4).png July 28, 2021

Model human diseases and select treatment

Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options

read more
Sylvia Boj_Corning.png July 27, 2021

Model inflammation in a dish

Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases.

read more
watch on demand (5).png May 18, 2021

Personalized Health Basel

Dr. Vries joins the monthly seminar series organized by the Personalized Health Basel (PHB) initiative

read more
virtual panel discussion.jpg July 20, 2020

Organoids for infectious disease

During this virtual mini-symposium co-hosted with our partner STEMCELL Technologies we discuss the development and…

read more


Below you can find a selection of our available resources, from brochures to podcasts and whitepapers. If you can’t find what you’re looking for please contact us at

Accelerating oncology drug discovery with HUB Organoids

Reduce oncology drug attrition rates with the only technology that brings "a patient in the lab"

download white paper
License HUB Organoid Technology

HUB Organoid Technology is based on the ground-breaking discovery of Lgr5+ stem cells in the adult intestine that led to the development of the fist “mini-gut in a dish”. HUB Organoid Technology does not require reprogramming or transformation of stem cells, therefore enabling the development of diseased as well as healthy organoids which preserve the original tissue genetic and epigenetic make up, including clinically-relevant mutations.

Our protocols have been developed, optimized, and standardized for a range of organs and disease types to allow the development of living biobanks of patient-derived organoids that are stable in long-term culture, can be expanded and cryopreserved for multiple applications.

Discover how to bring our unique models and know-how in house

download now
Flyer: HUB Tumor Organoid Models

Patient-derived models for next-gen drug discovery and development

download our flyer
Flyer: Cystic Fibrosis Organoid Models

HUB Cystic Fibrosis Organoid Models

Flyer: HUB Immuno-Oncology Organoid Models

HUB Immuno-Oncology Organoid Models

Brochure: HUB Organoids A Patient in the Lab

HUB Organoids: a Patient in the Lab

Flyer: HUB Toxicology Organoid Models

HUB Toxicology Organoid Models